Fiscal Period | 2024 | 2023 | 2022 | 2021 |
---|---|---|---|---|
Period End Date | Mar 24 | Mar 23 | Mar 22 | Mar 21 |
Net Income/ Starting Line | 219.54 | 134.10 | 83.04 | 127.09 |
Depreciation/ Depletion | 14.94 | 16.26 | 16.95 | 20.13 |
Non- Cash Items | -22.01 | -21.06 | -7.29 | -5.93 |
Changesin Working Capital | -184.60 | -71.01 | 8.10 | -36.51 |
Cashfrom Operating Activities | 27.86 | 58.29 | 100.80 | 104.78 |
Capital Expenditures | -10.76 | -8.52 | -9.62 | -7.71 |
Other Investing Cash Flow Items Total | 32.51 | 26.63 | 14.36 | 180.74 |
Cashfrom Investing Activities | 21.74 | 18.11 | 4.74 | 173.03 |
Financing Cash Flow Items | -0.52 | -0.63 | -0.95 | -1.09 |
Total Cash Dividends Paid | -40.00 | -20.00 | -5.00 | -5.00 |
Issuance( Retirement)of Debt Net | -3.86 | -3.85 | -3.51 | -2.88 |
Cashfrom Financing Activities | -44.37 | -24.48 | -9.46 | -8.97 |
Net Changein Cash | 5.23 | 51.92 | 96.08 | 268.84 |
Cash Interest Paid | 0.52 | 0.63 | 0.95 | 1.09 |
Cash Taxes Paid | 56.43 | 40.82 | 24.79 | 32.56 |
Astrazeneca Pharma India Dividend Astrazeneca Pharma India Bonus Astrazeneca Pharma India News Astrazeneca Pharma India AGM Astrazeneca Pharma India Rights Astrazeneca Pharma India Splits Astrazeneca Pharma India Board Meetings Astrazeneca Pharma India Key Metrics Astrazeneca Pharma India Shareholdings Astrazeneca Pharma India Profit Loss Astrazeneca Pharma India Balance Sheet Astrazeneca Pharma India Q1 Results Astrazeneca Pharma India Q2 Results Astrazeneca Pharma India Q3 Results Astrazeneca Pharma India Q4 Results
Top GainersTop LosersIndian IndicesBSE Active StocksNSE Active Stocks